"Pharmaceutical headlines" super 20 biopharmaceutical companies listed in Hong Kong how to get out of the breaking circle

(2020/11/20) Samsung Biologics dissolves its generics joint venture with AZ to abolish the Rituxan imitation project; The three-year valuation has quadrupled! Dark market up 6.53%... (Click on the title to get the original article) "Pharmaceutical 1st Time" Samsung Biologics dissolved a generic joint venture with AZ to abolish the Rituxan imitation project According to South Korean media reports, Samsung Biologics, a subsidiary of Samsung Group, recently abandoned the development of Rituxan biosimilar SAIT101 (ingredient: rituximab, rituximab), a drug for the treatment of filtered lymphoma.
Samsung Bio is promoting it as its first product when it enters the bio business.
and British pharmaceutical company AstraZeneta decided in September to suspend research and development activities at its joint venture Archigen Biotech and liquidate its assets, according to a quarterly report released this week by Samsung Bio.
the headlines: Roche and Yan Jian are one less competitor.
"eight-point health news" the State Council pushed the hospital information, this health care commission just investigated the city did the right thing? Perhaps very few people notice, when to start, to the hospital do not have to queue so many, through the mobile phone can make an appointment registration, self-service machine can pay, the cloud can see the report.
Xu Ying, deputy director of the health bureau of Jintan District, Changzhou, Jiangsu Province, said that the key to hospital information construction is to let the pain point of medical treatment "no sense" disappear.
because of the "no sense", most people find it difficult to realize that an appointment registration program behind the hospital to do how much basic information construction work.
: Write a major medical record from 40 to 15 minutes.
Arterial Network: More than 20 biopharmaceutical companies listed in Hong Kong stocks how to get out of the breaking circle recently, the domestic biopharmaceutical company Baiji Shenzhou announced that it will seek to list on the A-share board, is expected to be completed in the first half of 2021.
previously, Baiji Shenzhou was listed in the U.S. and Hong Kong stocks in 2016 and 2018, respectively, and after the successful listing of the Company, Baiji Shenzhou may become the first pharmaceutical company to list in three places.
: on one side is the Hong Kong stock break tide, on the other side is the biomedical fever.
New Kangjie Deqi Pharmaceuticals is on the market today! The three-year valuation has quadrupled! Dark market up 6.53%! Deqi Pharmaceuticals-B officially landed in Hong Kong today, the 12th Hong Kong stock listed crown B pharmaceutical companies this year.
2016, Wedge Pharmaceuticals is an Asia Pacific clinical phase biopharmaceutical company focused on innovative anti-tumor drugs.
: The rise and fall on the first day of trading were about the same as the performance of the dark market.
Firestone Creation: The mainstream of new anti-tumor drugs - the current situation of targeted drug development and future market forecast According to the 2018 National Cancer Report, malignant tumor (cancer) has become a serious threat to the health of the Chinese group of major public health problems According to the latest statistics, malignant tumor deaths account for 23.91% of all deaths among residents, and the morbidity and mortality rate of malignant tumors have been on the rise for more than a decade, with more than 220 billion yuan spent annually on medical treatment caused by malignant tumors, and the situation of prevention and control is serious.
: China's tumor market target drug proportion will increase year by year.